Additionally, in our retrospective study, the effectiveness of nintedanib in suppressing a decline in DLCO in patients with IPF was higher in patients with higher than lower serum KL-6 or LDH levels [32]. This evidence concerns the gene MUC1 and idiopathic interstitial pneumonia.